UnitedHealth deal for Amedisys likely to close despite report of DOJ scutiny - analyst
Seeking Alpha News (Mon, 25-Mar 2:05 PM ET)
UnitedHealth deal for Amedisys likely to close despite report of DOJ scrutiny - analyst
Seeking Alpha News (Mon, 25-Mar 2:05 PM ET)
TipRanks (Mon, 25-Mar 6:40 AM ET)
Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results
Globe Newswire (Wed, 21-Feb 4:30 PM ET)
Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis
Globe Newswire (Thu, 8-Feb 7:30 AM ET)
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Amedisys trades on the NASDAQ stock market under the symbol AMED.
As of March 28, 2024, AMED stock price was flat at $92.46 with 101,763 million shares trading.
AMED has a beta of 0.22, meaning it tends to be less sensitive to market movements. AMED has a correlation of 0.02 to the broad based SPY ETF.
AMED has a market cap of $3.02 billion. This is considered a Mid Cap stock.
Last quarter Amedisys reported $571 million in Revenue and $.94 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.09.
In the last 3 years, AMED stock traded as high as $292.97 and as low as $69.37.
The top ETF exchange traded funds that AMED belongs to (by Net Assets): VTI, IJH, VB, VBR, VXF.
AMED has underperformed the market in the last year with a price return of +24.6% while the SPY ETF gained +33.7%. AMED has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.9% and -0.8%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
AMED support price is $91.85 and resistance is $93.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMED stock will trade within this expected range on the day.